medigraphic.com
Anales de la Sociedad Mexicana de Oftalmología y Archivos de la Asociación Para Evitar la Ceguera en México

2007, Number 4

<< Back Next >>

Rev Mex Oftalmol 2007; 81 (4)

Evaluación clínica y confocal de mitomicina-C en PRK

Flores-Gaitán A, Velasco-Ramos R, Baca-Lozada O, Viggiano-Austria D, Babayán-Sosa A

Language: Spanish
References: 20
Page: 199-204
PDF size: 512.07 Kb.


ABSTRACT

Purpose: To evaluate the results of the prophylactic use of mitomycin-C to inhibit haze formation after excimer laser photorefractive keratectomy (PRK).
Methods: This prospective descriptive longitudinal study comprised 30 eyes (15 patients). The inclusion criteria were a spherical equivalent correction over –4.00 diopters (D) and inadequate corneal thickness to allow a LASIK procedure.
After PRK the eyes were treated with a soaked micro sponge placed over the ablated area. Refraction, uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA), slit lamp evidence of corneal opacity (haze), specular microscopy and confocal microscopy were evaluated.
Results: No moderate or severe toxic or side effects were encountered postoperatively. No eye had a haze rate higher than 1 during the 6 month follow up. At 6 months all eyes had a stable refractive outcome with an UCVA of 20/25 or better in 79.99% of all eyes
Specular microscopy showed mean endothelial cell density of 2,632 cells/mm2 preoperatively and 2,644 cells/mm2 postoperatively. By confocal microscopy superficial epithelial cells acquired normal density at 1 month postoperatively, basal cells had a normal density after 3 months, the amount of activated keratocytes increased slowly during the first 3 months.
Conclusions: The prophylactic use of a diluted mitomycin-C 0.01% solution applied intraopetatively in a single dose after PRK decrease the incidence of haze.


REFERENCES

  1. Stein R. Photorefractive keratectomy. Int Ophthalmol Clin 2000; 40:35-56.

  2. Pallikaris IG, Papatznaki ME, Stathi EZ y cols. Laser in situ keratomileusis. Lasers Surg Med 1990; 10:463-468.

  3. Jackson WB y cols. Photorefractive keratectomy. En: Krachmer, Mannis, Holland. Cornea, vol. 2. 2a ed. USA, Elsevier Mosby, 2005. p. 1923-1938.

  4. Carones F y cols. Evaluation of the prophylactic use of mitomycin- C to inhibit haze formation after photorefractive keratectomy. J. Cataract Refract Surgery 2002; 28:2088-2095.

  5. Camellin M. Laser epithelial keratomilesis with mitomycin c: indications and limits. J Refrac Surg 2004; 20:693-698.

  6. Wilson SE, He Y-G, Weng J, Li Q, McDowall AW y cols. Epithelial injury induces keratocytes apoptosis: hypothesized role for the interleucin-1 system in the modulation of corneal tissue organization and wound healing. Exp Eye Res 1996; 62325-338.

  7. Erie JC, Patel SV, Mc Laren, JW, Maguirre LJ y cols. , Keratocyte density in vivo after photorefractive keratectomy in humans. Trans Am Ophthalmol Soc 1999; 97:221-36.

  8. Moller-Pedersen T, Li HF, Petroll WM y cols. Confocal microscopic characterization of wound repair after photorefractive keratectomy. Invest Ophthal Vis Sci 1998; 39:487-501.

  9. Talamo JH, Gollamudi S, Green WR y cols. Modulation of corneal wound healing after excimer laser keratomileusis using topical mitomycine C and steroids. Arch Ophthalmol 1991; 109:1141-1146.

  10. Porges Y y cols. Phototherapeutic keratectomy with mitomycin c for corneal haze following photorefractive keratectomy for myopia. J Refract Surg 2003; 19:40-43.

  11. Calabresi P, Chabner BA. Antineoplastic agents. En: Goodman Gilman A, Rall TW, Nies AS, Taylor P (eds.). Pharmacological Basis of Therapeutics. 8a ed. New York, Pegamon Press, 1990.

  12. Sugar A. Who should receive mitomycin-C after pterygium surgery? Ophthalmology 1992; 99:1645-6.

  13. Palmer SS. Mitomycin as adjunct chemotherapy with trabeculotomy. Ophthalmology 1991; 98:317-21.

  14. Talamo JK, Gollamudi S, Green WR y cols. Modulation of corneal wound healing after excimer laser keratomileusis using topical mitomycin-C and steroids. Arch Ophthalmol 1991; 109:1141-6.

  15. Schipper I, Suppelt C, Getters JO. Mitomycin-C reduces scar formation after excimer laser (193nm) photorefractive keratectomy in rabbits. Eye 1997; 11:649-55.

  16. Probst V LE. PRK Complications and their management. En: Jeffery J. Excimer laser refractive surgery, practice and principles. Canada, SLACK, 1996. p. 169-208.

  17. Majmudar PA y cols. Topical mitomycin-c for subepitelial fibrosis after refractive corneal surgery. Ophthalmology 2000; 107:89-94.

  18. Rubinfeld RS y cols. Serious complications of topical mitomycin- C after pterigium surgery. Ophthalmology 1992; 99:1646-1654.

  19. Dougherty PJ y cols. Corneoscleral melt after pterigium surgery using a single intraoperative application of mitomycin-C. Cornea 1996; 15:537-540.

  20. Cavan HD y cols. Clinical and diagnostic use of in vivo confocal microscopy in patients with corneal disease. Ophthalmology 1993; 100:1444-1454.




2020     |     www.medigraphic.com